Details of issuance or disposal
Series 7 Stock Acquisition Rights (with an exercise price adjustment provision) through a third-party allotment
291,000 shares delivered upon exercise of the Series 7 Stock Acquisition Rights (291,000 new shares and 0 transferred treasury shares)
The lower thin line represents the existing number of shares to which these shares will be added.
Approximately 6.28% (291,000 shares / 4,634,098 shares outstanding as of the end of the month preceding the relevant month)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Series 7 Stock Acquisition Rights (with an exercise price adjustment provision) through a third-party allotment |
| Number of shares to be issued or disposed of | 291,000 shares delivered upon exercise of the Series 7 Stock Acquisition Rights (291,000 new shares and 0 transferred treasury shares) |
| Intended allottee | GP上場企業出資投資事業有限責任組合 (not identified in the text as the allottee of the Series 7 Stock Acquisition Rights) |
| Dilution Rate | Approximately 6.28% (291,000 shares / 4,634,098 shares outstanding as of the end of the month preceding the relevant month) |
| Total number of issued shares | 4,634,098 shares (as of the end of the month preceding the relevant month) → 4,925,098 shares (simple calculation)(Approximately 6.28%) |
| Exercise price | The Series 7 Stock Acquisition Rights have an exercise price adjustment provision. The exercise prices in October 2026 were ¥192, ¥191, ¥278, ¥229, ¥210, ¥197, ¥184 and ¥180. The adjustment floor is Not disclosed |
| Number of Stock Acquisition Rights | The total number of Series 7 Stock Acquisition Rights is Not disclosed; 2,910 were exercised during the relevant month, and 1,318 remained unexercised at month-end. 8,288 Series 6 Stock Acquisition Rights remained unexercised at month-end |
| Procedures under the Corporate Code of Conduct | Disclosure of compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange Securities Listing Regulations and the Japan Securities Dealers Association Rules Concerning the Handling of Third-Party Allotments, etc. The number of shares delivered across all series was 291,000, the number of listed shares as of the payment date for the issuance was 2,911,799, and the exercise ratio subject to the exercise restrictions was 10.0%. |
| Most recent equity financing | Timing 14 April 2025 / Type Series 6 Stock Acquisition Rights and Series 1 Unsecured Convertible Bonds with Stock Acquisition Rights / Amount Not disclosed, Timing 15 June 2026 / Type Series 7 Stock Acquisition Rights (with an exercise price adjustment provision) / Amount Not disclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Series 6 Stock Acquisition Rights and Series 1 Unsecured Convertible Bonds with Stock Acquisition Rights are deemed “MSCBs, etc.” under the rules of the Tokyo Stock Exchange in connection with the issuance of the Series 7 Stock Acquisition Rights (with an exercise price adjustment provision), and therefore monthly exercise status is disclosed.